Alnylam Pharmaceuticals Slumps to 481st in Trading Volume Despite FDA and EMA Milestones

On May 20, 2025, Alnylam Pharmaceuticals (ALNY) experienced a significant decline, with a trading volume of $182 million, marking a 32.51% decrease from the previous day. This placed the company at the 481st position in terms of trading volume for the day. The stock price of Alnylam Pharmaceuticals (ALNY) fell by 0.06%.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of August 11, 2025. This acceptance marks a significant milestone for Alnylam, as it brings the company one step closer to potentially bringing a new treatment option to patients suffering from this rare and debilitating disease.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). The validation of the MAA marks an important step in the regulatory review process for patisiran in the European Union. The EMA's validation confirms that the application is complete and that the review process can begin. This is a significant development for Alnylam, as it brings the company closer to potentially offering a new treatment option to patients suffering from this rare and debilitating disease in Europe.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the company has entered into a strategic collaboration with a leading biopharmaceutical company to develop and commercialize a new RNAi therapeutic for the treatment of a rare genetic disorder. Under the terms of the agreement, Alnylam will receive an upfront payment of $50 million and is eligible to receive additional milestone payments and royalties on future sales of the product. This collaboration is a testament to Alnylam's leadership in the field of RNAi therapeutics and its commitment to developing innovative treatments for rare diseases.